This study is the first to inject repeated doses of stem cells intravenously into patients who have heart failure due to a heart attack or coronary artery disease.
The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the bispecific T-cell engager blinatumomab (Blincyto) to chemotherapy ...